Delcath Systems, Inc. (NASDAQ:DCTH – Get Rating) COO John Purpura bought 3,300 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was bought at an average cost of $4.61 per share, for a total transaction of $15,213.00. Following the completion of the purchase, the chief operating officer now directly owns 27,021 shares of the company’s stock, valued at $124,566.81. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
John Purpura also recently made the following trade(s):
- On Monday, April 11th, John Purpura acquired 5,000 shares of Delcath Systems stock. The shares were bought at an average price of $6.59 per share, for a total transaction of $32,950.00.
Shares of NASDAQ:DCTH opened at $4.50 on Thursday. Delcath Systems, Inc. has a 12-month low of $4.30 and a 12-month high of $13.50. The company has a quick ratio of 2.70, a current ratio of 2.93 and a debt-to-equity ratio of 2.55. The stock’s 50-day moving average price is $6.05 and its 200-day moving average price is $7.32.
Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP purchased a new position in shares of Delcath Systems in the first quarter valued at about $75,000. Virtu Financial LLC purchased a new position in Delcath Systems during the 4th quarter valued at about $114,000. State Street Corp raised its position in Delcath Systems by 70.3% during the 4th quarter. State Street Corp now owns 25,200 shares of the company’s stock valued at $195,000 after purchasing an additional 10,400 shares during the last quarter. Susquehanna International Group LLP bought a new position in Delcath Systems in the 4th quarter worth $209,000. Finally, Millennium Management LLC purchased a new stake in shares of Delcath Systems in the 2nd quarter worth about $405,000. 21.93% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently issued reports on DCTH. Canaccord Genuity Group cut their price objective on Delcath Systems from $24.00 to $20.00 and set a “buy” rating for the company in a report on Monday, April 11th. StockNews.com assumed coverage on shares of Delcath Systems in a research report on Friday, May 13th. They set a “sell” rating on the stock.
Delcath Systems Company Profile (Get Rating)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.